One Of The Five Cyclos Is Five-membered And Includes Ring Chalcogen (e.g., Codeine, Morphine, Etc.) Patents (Class 514/282)
  • Patent number: 11139056
    Abstract: The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.
    Type: Grant
    Filed: September 2, 2019
    Date of Patent: October 5, 2021
    Assignee: Nalpropion Pharmaceuticals LLC
    Inventors: Preston Klassen, Kristin Taylor
  • Patent number: 11129826
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: September 28, 2021
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 11103581
    Abstract: An abuse deterrent pharmaceutical composition including an acid soluble salt of a pharmaceutically active ingredient and a buffering ingredient; wherein the acid soluble salt of the pharmaceutically active ingredient and the buffering ingredient retard release of the pharmaceutically active ingredient when the composition is ingested in excess of an intended dosage.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: August 31, 2021
    Assignee: Acura Pharmaceuticals, Inc.
    Inventor: Robert Barnett Jones
  • Patent number: 11083794
    Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: August 10, 2021
    Assignee: Acura Pharmaceuticals, Inc.
    Inventors: Albert W. Brzeczko, R. Gary Hollenbeck
  • Patent number: 11071734
    Abstract: A tableted pharmaceutical composition contains nalfurafine or a pharmaceutically acceptable acid addition salt thereof and is excellent in formability and quality control of related substances. The tableted pharmaceutical composition includes nalfurafine or a pharmaceutically acceptable acid addition salt thereof, a binder component, and a carrier, wherein the above mentioned nalfurafine or a pharmaceutically acceptable acid addition salt thereof is contained in an amount of 0.1 to 10 ?g, and the weight of the above mentioned binder component is 100,000 to 2,000,000 weight % based on the weight of the above mentioned nalfurafine or a pharmaceutically acceptable acid addition salt thereof and 5 to 20 weight % based on the total weight of the resulting pharmaceutical composition, or 20,000 to 500,000 weight % and 1 to 5 weight % based on the total weight of the resulting pharmaceutical composition.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: July 27, 2021
    Assignee: Toray Industries, Inc.
    Inventors: Satoshi Minakami, Suguru Takaki, Kotoe Ohta, Yasuhide Horiuchi
  • Patent number: 11045478
    Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: June 29, 2021
    Assignee: ESSENTIALIS, INC.
    Inventors: Neil M. Cowen, Khaled A. Yamout
  • Patent number: 11026939
    Abstract: Solid pharmaceutical compositions with high drug loading are provided. A formulation useful for the solid pharmaceutical composition includes valbenazine, or a pharmaceutically acceptable salt thereof, silicified microcrystalline cellulose, isomalt, hydroxypropyl methylcellulose, partially pregelatinized maize starch, and magnesium stearate.
    Type: Grant
    Filed: October 19, 2020
    Date of Patent: June 8, 2021
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Richard Alexander Moore, Jr., Gregory A. McClelland, Christopher F. O{grave over ( )}Brien
  • Patent number: 11014933
    Abstract: Non-peptide MOR opioid receptor modulators are provided. The compounds exhibit predominantly central activity and are used to treat e.g. substance use disorders, and pain.
    Type: Grant
    Filed: December 24, 2019
    Date of Patent: May 25, 2021
    Assignee: VIRGINIA COMMONWEALTH UNIVERSITY
    Inventor: Yan Zhang
  • Patent number: 10988481
    Abstract: Analogues of 6 ?/?-naltrexamine (NAQ) are provided. The analogues are selective, reversible antagonists of the mu opioid receptor (MOR) that exhibit good blood brain barrier penetration. The compounds are used in the treatment of opioid addiction and other diseases and conditions, including for the treatment of pain.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: April 27, 2021
    Assignee: Virginia Commonwealth University
    Inventors: Yan Zhang, Dana E. Selley, William Dewey, Hamid Abkarali
  • Patent number: 10987350
    Abstract: Disclosed and described is a novel dose titration procedure for administering the opioid antagonist, nalmefene, to a patient diagnosed with post-traumatic stress disorder (PTSD).
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: April 27, 2021
    Inventors: Hillel Glover, Lillian Hahn
  • Patent number: 10973814
    Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: April 13, 2021
    Assignee: HIKMA PHARMACEUTICALS USA INC.
    Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda
  • Patent number: 10967065
    Abstract: In some aspects, pegylated aminoglycoside compounds are provided. In some embodiments, m-PEG-tobramycin compounds may be used to treat a biofilm infection or reduce or treat established biofilms.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: April 6, 2021
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Hugh Smyth, Ju Du
  • Patent number: 10960077
    Abstract: A liquid or semi-solid matrix or magma or paste which is non-newtonian, thixotropic and pseudoplastic and composed of one or more controlled release agent, and/or one or more clays such as bentonite and/or one or more fillers in a non aqueous vehicle, and optionally materials selected from disintegrants, humectants, surfactants and stabilizers. The composition and physicochemical properties makes it harder or prevents dose dumping of narcotic analgesics in the presence of alcohol and harder to abuse opiod agonists or narcotic analgesics and discourages drug abuse via crushing, milling or grinding the dosage form to powder or heating the dosage form to vapour and snorting or inhalation by the nasal route or dissolving to abuse via the parenteral route.
    Type: Grant
    Filed: May 12, 2006
    Date of Patent: March 30, 2021
    Assignee: Intellipharmaceutics Corp.
    Inventors: Isa Odidi, Amina Odidi
  • Patent number: 10925870
    Abstract: Disclosed is a method for reducing or preventing fetal opioid dependence in a drug dependent or opioid tolerant pregnant subject. The method involves administering to the pregnant subject a composition comprising an opioid antagonist in an amount effective to reduce or prevent fetal opioid dependence, wherein the opioid antagonist a) is orally available or delivered systemically and reaches the circulation of the pregnant subject, b) is substantially excluded from the subject's brain by the blood brain barrier, and c) penetrates the placenta and enters the fetal brain. The method also includes administering the opioid antagonist to the neonate in increasing amounts to facilitate weaning the neonate from continued opioid maintenance.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: February 23, 2021
    Assignee: Ohio State Innovation Foundation
    Inventors: Wolfgang Sadee, John Oberdick
  • Patent number: 10870654
    Abstract: Compositions comprising hydrocodone benzoic acid enol ester to form novel prodrugs including hydrocodone benzoic acid enol ester salts, and various polymorphs. Also provided are processes for the preparation of hydrocodone benzoic acid enol ester salts, and various polymorphs.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: December 22, 2020
    Assignee: KemPharm, Inc.
    Inventors: Travis Mickle, Sven Guenther, Christal Mickle, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
  • Patent number: 10865186
    Abstract: Provided are compounds, including those of Formula I; and pharmaceutically acceptable salts and solvates thereof. The compounds described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: December 15, 2020
    Assignee: Nektar Therapeutics
    Inventors: Franco J. Duarte, Neel K. Anand, Pankaj Sharma, Devendrapratap Singh
  • Patent number: 10828294
    Abstract: The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: November 10, 2020
    Assignee: Nalpropion Pharmaceuticals LLC
    Inventors: Preston Klassen, Kristin Taylor
  • Patent number: 10806731
    Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUP ) / EC 50 ] [ C max ? ( ANTAGONIST ) / IC 50 ] .
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: October 20, 2020
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel R. Deaver, Elliot Ehrich
  • Patent number: 10799545
    Abstract: Transdermal delivery devices for the delivery of cannabidiol (CBD) and related moieties are shown and described. In a reservoir-patch design, a microporous, hydrophilic membrane and a backing define a reservoir that houses a mixture of CBD, a polar liquid, and a gelling agent, along with other moieties that seem to be enhanced or bioavailability of increased by the same. The hydrophilic membrane is coated with an amine-compatible silicone skin adhesive. In a monolithic design, a release liner is coated with a mixture of CBD and a PIB or amine-compatible silicone skin adhesive laminated to the backing material. In using CBD as a pure compound or as one to combine with other moieties, the invention is able to control delivery better than the prior art. Construction of the transdermal patch of reservoir type is also taught, which enables things such as Vitamin B12 to become part of the complex deliverable by the inventions.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: October 13, 2020
    Assignee: Remy Biosciences, Inc.
    Inventor: Ludwig Weimann
  • Patent number: 10744132
    Abstract: An injectable pharmaceutical composition includes a solution of 3-acyl-buprenorphine, or a pharmaceutically acceptable salt thereof, in a biocompatible organic solvent, wherein the injectable pharmaceutical composition exhibits a steady release profile lasting over one week when injected into a patient. The acyl group is an alkylcarbonyl group, and an alkyl portion of the alkylcarbonyl group is a straight-chain, branched-chain, having 1-20 carbon atoms. The biocompatible organic solvent is N-methyl-2-pyrrolidone, ethyl acetate, ethanol, butanol, 2-butanol, isobutanol, ispropanol, glycerin, benzyl benzoate, dimethyl sulfoxide, N,N-dimethylacetamide, propylene glycol, dimethyl glycol, benzyl alcohol, or a combination of two or more thereof.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: August 18, 2020
    Assignee: Alar Pharmaceuticals, Inc.
    Inventors: Tong-Ho Lin, Yung-Shun Wen, Jui-Wei Liang
  • Patent number: 10702480
    Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: July 7, 2020
    Assignee: OHEMO Life Sciences, Inc.
    Inventors: Manish S. Shah, Ray J. DiFalco
  • Patent number: 10696684
    Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: June 30, 2020
    Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P, RHODES TECHNOLOGIES
    Inventors: Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper
  • Patent number: 10695343
    Abstract: A method for inducing a sustained immune response in humans or animal patient suffering from human immunodeficiency virus (HIV) acquired immune deficiency syndrome (AIDS, autoimmune disease, cancer, inflammation, and neurodegenerative diseases comprises daily administration to such patients a single oral tablet, rapidly dissolving film, capsule, liquid or cream dose of an Immediate release naltrexone composition comprising between about 0.01 to about 10 mg of naltrexone. In order to provide a benefit the naltrexone must be an Immediate release composition comprising between about 0.01 and about 10 mg of naltrexone.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: June 30, 2020
    Inventors: Noreen Griffin, Fengping Shan, Nicholas Plotnikoff
  • Patent number: 10695324
    Abstract: The present invention generally relates to a method of treating or preventing an endoplasmic reticulum stress disorder in subjects, such as a method of treating or preventing Wolfram syndrome.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: June 30, 2020
    Assignee: Washington University
    Inventors: Fumihiko Urano, Simin Lu
  • Patent number: 10695342
    Abstract: Abuse-resistant opioid compounds, drug delivery systems, pharmaceutical compositions comprising an opioid covalently bound to a chemical moiety are provided. Methods of delivering an active ingredient to a subject and methods of preventing opioid abuse are also provided.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: June 30, 2020
    Assignees: ALBANY MOLECULAR RESEARCH, INC., 3ST RESEARCH LLC
    Inventors: Matthew Surman, John K. Thottathil, Kathryn Golden, Paolo Pasetto, Xiaomin Jin, Xiaowu Jiang, Fatoumata Camara
  • Patent number: 10689389
    Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: June 23, 2020
    Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P., RHODES TECHNOLOGIES
    Inventors: Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper
  • Patent number: 10653632
    Abstract: The present disclosure relates generally to binder powders for use in powder material processing and processes for their preparation. The disclosure further relates to binder powders for use in making solid powder compact forms, solid powder compact forms containing said binder powders and methods for making solid powder compact forms.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: May 19, 2020
    Assignee: Monash University
    Inventors: David Morton, Laurence Orlando, Tony Qi Zhou, Louise Chia-Hua Ho
  • Patent number: 10638786
    Abstract: Methods and compositions are provided directed to decreasing visceral fat in subjects. Visceral fat is directly linked to cardiovascular and metabolic disease risk. The methods describe a calorie restricted diet of specific percentages of food elements to be consumed within a specific time period each day. Calorie restriction and nutrient percentages take into consideration average daily normal activity of subjects as well as baseline health metrics including estimated amount of visceral fat. Remarkable results are obtained since visceral fat is targeted for reduction, thereby markedly reducing the risk of cardiovascular and metabolic disease.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: May 5, 2020
    Assignee: Zolighter, LLC
    Inventors: Jessica Barnes, Gerald Dembrowski
  • Patent number: 10632205
    Abstract: A pharmaceutical paste composition comprising an active ingredient such as an addictive substance, a controlled release agent, and a pharmaceutically suitable aqueous or non-aqueous carrier. The composition may comprise one or more of a clay, or an oily, waxy, or fatty substance. The composition may be filled into a capsule or other dispensing device. The composition may reduce dose dumping of an active ingredient. Methods of making and using the composition are also described.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: April 28, 2020
    Assignee: INTELLIPHARMACEUTICS CORP
    Inventors: Isa Odidi, Amina Odidi
  • Patent number: 10604488
    Abstract: The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as methods for using the (+)-morphinans to treat pain. Also provided are pharmaceutical combination compositions comprising a (+)-morphinan and an opioid agonist/monoamine reuptake inhibitor, as well as methods for using the combination compositions to treat pain.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: March 31, 2020
    Assignee: Mallinckrodt LLC
    Inventors: Bobby N. Trawick, David W. Berberich, Christopher W. Grote
  • Patent number: 10588973
    Abstract: The embodiments provide a percutaneous absorption composition for a basic medicament having improved transdermal absorbability. The percutaneous absorption composition comprises a sorbic acid and/or a metal sorbate as a percutaneous absorption promotor. The molar ration of the sorbic acid and/or the metal sorbate to the basic medicament is 0.5-2.5. The composition of the present disclosure may further comprise a basic component.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: March 17, 2020
    Assignee: MEDRx Co., LTD
    Inventors: Yasushi Miwa, Hidetoshi Hamamoto, Naoya Akazawa
  • Patent number: 10576045
    Abstract: The present invention provides a pharmaceutical composition comprising a selective serotonin reuptake inhibitor (SSRI) and a norepinephrine reuptake inhibitor (NRI), particularly, fluoxetine and reboxetine, for treating obesity. Surprisingly, the inventor of the present invention discovered that use of especially low doses of the active compounds, particularly, at most 6 mg/day of reboxetine and at most 20 mg/day of fluoxetine, wherein the reboxetinerfluoxetine ratio is from about 1:4 to about 1:6, induces an effective weight loss in obese patients. Advantageously, the combinations of the present invention include very low doses of the active ingredients, thereby decreasing possible drug-drug interactions and adverse drug reaction.
    Type: Grant
    Filed: February 15, 2012
    Date of Patent: March 3, 2020
    Inventor: Nir Barak
  • Patent number: 10561628
    Abstract: An object of the present invention is to provide [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid monobenzenesulfonate as a stabilized pharmaceutical solid preparation, and also to provide a method for preparing the stabilized pharmaceutical solid preparation. The object can be attained by a pharmaceutical solid preparation comprising [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid monobenzenesulfonate which is a compound represented by the following formula (I) in combination with (i) one or two or more excipients, (ii) one or two or more disintegrants, and (iii) a specific antioxidant.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: February 18, 2020
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Shinichiro Tajiri, Jin Hisazumi, Shinji Yoshinaga, Hiroyuki Fujimori, Hiroaki Arai
  • Patent number: 10555916
    Abstract: A method of treating a pervasive development disorder in a subject includes administering to the subject an amount of an NMDAR antagonist effective to ameliorate biochemical and functional abnormalities in the subject associated with loss-of-function mutations of the gene encoding methyl-CpG binding protein 2 (MeCP2).
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: February 11, 2020
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventor: David M. Katz
  • Patent number: 10517841
    Abstract: 5-HT receptor agonists are useful in the treatment of a variety of diseases. Provided herein are methods of treating and/or reducing the occurrence of respiratory depression caused by an opioid in a human patient or patient population using a 5-HT receptor agonist, such as, for example, a 5-HT4 agonist (e.g., fenfluramine). Methods of stimulating one or more 5-HT4 receptors in the brain of a patient undergoing treatment with an opioid, wherein the patient is at risk of respiratory depression, by administering a 5-HT4 agonist (e.g., fenfluramine) to a subject in need thereof are provided. Pharmaceutical compositions for use in practicing the subject methods are also provided.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: December 31, 2019
    Assignee: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Bradley S. Galer, Carl L. Faingold, Parthena Martin
  • Patent number: 10449190
    Abstract: The invention describes pharmaceutical compounds and compositions comprised of a ligand attached to opioids in a manner that substantially decreases or deters the potential for opioid abuse, addiction, illicit and illegal use, and overdose. When delivered at the proper dosage, the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: October 22, 2019
    Inventor: John K. Thottathil
  • Patent number: 10449235
    Abstract: Some embodiments are directed to the use of creatine kinase or fragments thereof which induce analgesia, and also to the use of pharmaceutical compositions including the same, to relieve pain.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: October 22, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE STRASBOURG
    Inventors: Yannick Goumon, Jinane Mouheiche, Alexis Laux-Biehlmann, Pierrick Poisbeau, Nisrine Kamoun
  • Patent number: 10441657
    Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: October 15, 2019
    Assignee: ABUSE DETERRENT PHARMACEUTICALS, LLC
    Inventors: Albert W. Brzeczko, R. Gary Hollenbeck
  • Patent number: 10441585
    Abstract: Immediate release, oral, pharmaceutical formulation comprising nalbuphine or a pharmaceutically acceptable salt thereof, and at least one hydrophilic granulation carrier, one hydrophilic binder and one lubricant.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: October 15, 2019
    Assignee: DEBREGEAS ET ASSOCIES PHARMA
    Inventors: Christophe Lebon, Pascal Suplie, David Olivier Paul
  • Patent number: 10441537
    Abstract: Methods of treating a heart condition include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. Nebulized drug product and kits are also contemplated.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: October 15, 2019
    Assignee: InCarda Therapeutics, Inc.
    Inventors: Carlos Schuler, Rangachari Narasimhan, Luiz Belardinelli, Prashanti Madhavapeddi
  • Patent number: 10406153
    Abstract: The invention is directed to processes for the preparation of benzhydrocodone hydrochloride. More particularly, the invention is directed to processes for a one-pot synthesis of benzhydrocodone hydrochloride of improved yield and/or purity.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: September 10, 2019
    Assignee: Noramco, Inc.
    Inventors: Wen-Chun Zhang, Bruce P. Johnson
  • Patent number: 10403170
    Abstract: The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: September 3, 2019
    Assignee: Nalpropion Pharmaceuticals, Inc.
    Inventors: Preston Klassen, Kristin Taylor
  • Patent number: 10376584
    Abstract: Stable pharmaceutical compositions useful for administering methylnaltrexone are described, as are methods for making the same. Kits, including these pharmaceutical compositions, also are provided.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: August 13, 2019
    Assignee: Progenics Pharmaceuticals, Inc.
    Inventors: Suketu P. Sanghvi, Thomas A. Boyd
  • Patent number: 10370382
    Abstract: There is provided a novel process for the preparation of a compound of formula (I), wherein R1 is as described in the description, by demethylation of a corresponding O-methyl derivative.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: August 6, 2019
    Assignee: Cambrex Charles City, Inc.
    Inventors: Pär Holmberg, Michael Robert Tracey, Zhiming Eric Dong
  • Patent number: 10351574
    Abstract: Compositions comprising hydrocodone benzoic acid enol ester to form novel prodrugs including hydrocodone benzoic acid enol ester salts, and various polymorphs. Also provided are processes for the preparation of hydrocodone benzoic acid enol ester salts, and various polymorphs.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: July 16, 2019
    Assignee: KemPharm, Inc.
    Inventors: Travis Mickle, Sven Guenther, Christal Mickle, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
  • Patent number: 10314838
    Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ c ma ? ? x ? ( BUP ) / EC 50 ] [ c ma ? ? x ? ( ANTAGONIST ) / IC 50 ] .
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: June 11, 2019
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Elliot Ehrich
  • Patent number: 10300015
    Abstract: The present invention relates to a homogeneous, stable, and palatable pharmaceutical solution comprising baclofen, sorbitol and naltrexone.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: May 28, 2019
    Assignee: Pharnext
    Inventors: Daniel Cohen, Ilya Chumakov, Serguei Nabirochkin, Viviane Bertrand
  • Patent number: 10292972
    Abstract: A pharmaceutical composition containing an anticancer compound, named isopicrinine, isolated from the plant Rhazya Stricta. The pharmaceutical composition may contain a salt, an analog, a derivative, and/or the prodrug of isopicrinine. A method of treating cancer with the pharmaceutical composition is disclosed. A method of extracting isopicrinine is also disclosed.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: May 21, 2019
    Assignee: King Abdulaziz University
    Inventors: Jamal Sabir M. Sabir, Abdullah Y. Obaid, Nahid H. Hajrah, Waseem Mohammed, Zainab H. Abdul-Hameed, Walied M. Alarif, Roop Singh Bora, Seif-Eldin N. Ayyad, Nouf Saeed A. Al-Abbas, Abdulkader M. Shaikh Omer, Mohammed Zainy Mutawakil, Neil Hall, Kulvinder Singh Saini
  • Patent number: 10278967
    Abstract: The present disclosure provides acetate salts of buprenorphine, and its anhydrates, solvates, hydrates, and crystalline forms thereof, where the acetate salts of buprenorphine are essentially free of impurities. The disclosure further provides method of preparing the acetate salts, buprenorphine free base prepared from the acetate salts, other salts prepared from the free base, and pharmaceutical compositions thereof essentially free of impurities.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: May 7, 2019
    Assignee: Rhodes Technologies
    Inventors: C. Frederick M. Huntley, Erik Wayne Kataisto, Helge Alfred Reisch, Archana Sharma
  • Patent number: 10258235
    Abstract: The present invention provides a method for assessing bowel function in a patient, comprising providing the patient with a numeric analog scale for at least one parameter which is a measure of bowel function; causing the patient to indicate on the numeric analog scale the amount and/or intensity of the parameter being experienced; and observing the amount and/or intensity of the at least one parameter indicated on the numeric analog scale in order to assess bowel function.
    Type: Grant
    Filed: February 28, 2006
    Date of Patent: April 16, 2019
    Assignee: Purdue Pharma L.P.
    Inventors: Petra Leyendecker, Michael Hopp, Axel Drews